$SANA
Sana Biotechnology Inc

2022 Q3 Form 10-Q Financial Statement

#000156459022028036 Filed on August 04, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2022 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $15.51M $18.29M $14.43M
YoY Change 15.49% 46.61% 37.21%
% of Gross Profit
Research & Development $76.74M $72.54M $72.69M
YoY Change 44.12% 61.21% -56.97%
% of Gross Profit
Depreciation & Amortization $4.000M $3.800M $3.600M
YoY Change 42.86% 46.15% 63.64%
% of Gross Profit
Operating Expenses $76.74M $72.54M $31.69M
YoY Change -8.03% 61.21% -82.47%
Operating Profit -$86.19M -$72.90M -$31.69M
YoY Change 3.3% -492.97% -82.47%
Interest Expense $1.173M $637.0K $339.0K
YoY Change 642.41% 390.0% 180.17%
% of Operating Profit
Other Income/Expense, Net -$106.0K -$198.0K -$102.0K
YoY Change -1160.0% -19900.0% -884.62%
Pretax Income -$85.12M -$72.47M -$31.45M
YoY Change 2.23% -487.87% -82.59%
Income Tax
% Of Pretax Income
Net Earnings -$85.12M -$72.47M -$31.45M
YoY Change 2.23% -487.87% -82.59%
Net Earnings / Revenue
Basic Earnings Per Share -$0.45 -$0.39 -$0.17
Diluted Earnings Per Share -$0.45 -$0.39 -$169.1K
COMMON SHARES
Basic Shares Outstanding 190.2M 187.6M 186.0M
Diluted Shares Outstanding 189.3M 187.6M 186.0M

Balance Sheet

Concept 2022 Q3 2022 Q2 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $485.8M $484.8M $512.4M
YoY Change -19.54% -43.15% -46.64%
Cash & Equivalents $163.3M $194.7M $197.3M
Short-Term Investments $322.4M $290.1M $323.9M
Other Short-Term Assets $14.50M $9.612M $10.84M
YoY Change 58.75% 28.09% 50.58%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $500.3M $494.4M $523.2M
YoY Change -18.37% -42.53% -45.92%
LONG-TERM ASSETS
Property, Plant & Equipment $67.35M $67.85M $68.69M
YoY Change 6.15% 15.64% 34.73%
Goodwill $140.6M $140.6M
YoY Change 0.02% 0.02%
Intangibles $59.20M $59.20M
YoY Change -0.01% -0.01%
Long-Term Investments $25.82M $94.76M $145.0M
YoY Change -90.16% 21.6% 571.36%
Other Assets $4.717M $4.825M $13.72M
YoY Change -49.87% 76.03% 389.96%
Total Long-Term Assets $397.9M $476.7M $524.4M
YoY Change -35.82% 19.32% 55.61%
TOTAL ASSETS
Total Short-Term Assets $500.3M $494.4M $523.2M
Total Long-Term Assets $397.9M $476.7M $524.4M
Total Assets $898.1M $971.1M $1.048B
YoY Change -27.15% -22.92% -19.69%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.993M $3.079M $4.765M
YoY Change 1.17% -16.87% 10.81%
Accrued Expenses $49.14M $39.01M $35.06M
YoY Change 34.77% 28.23% 55.81%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $114.8M $97.11M $93.51M
YoY Change 24.78% 126.72% 165.65%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $217.3M $234.5M $252.4M
YoY Change -30.06% 43402.04% -34.82%
Total Long-Term Liabilities $217.3M $234.5M $252.4M
YoY Change -30.06% 43402.04% -34.82%
TOTAL LIABILITIES
Total Short-Term Liabilities $114.8M $97.11M $93.51M
Total Long-Term Liabilities $217.3M $234.5M $252.4M
Total Liabilities $332.1M $331.6M $346.0M
YoY Change -17.53% 664.53% -18.12%
SHAREHOLDERS EQUITY
Retained Earnings -$974.4M -$889.3M -$816.8M
YoY Change 44.44% 50.37% 33.9%
Common Stock $19.00K $19.00K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $566.0M $639.5M $701.7M
YoY Change
Total Liabilities & Shareholders Equity $898.1M $971.1M $1.048B
YoY Change -27.15% -22.92% -19.69%

Cashflow Statement

Concept 2022 Q3 2022 Q2 2022 Q1
OPERATING ACTIVITIES
Net Income -$85.12M -$72.47M -$31.45M
YoY Change 2.23% -487.87% -82.59%
Depreciation, Depletion And Amortization $4.000M $3.800M $3.600M
YoY Change 42.86% 46.15% 63.64%
Cash From Operating Activities -$64.80M -$71.48M -$77.71M
YoY Change 28.34% 76.23% 55.69%
INVESTING ACTIVITIES
Capital Expenditures -$4.350M -$4.391M $7.533M
YoY Change -46.06% -56.76% 16.97%
Acquisitions
YoY Change
Other Investing Activities $36.21M $82.12M $20.08M
YoY Change -120.36% -426.3% -63.84%
Cash From Investing Activities $31.86M $77.73M $12.55M
YoY Change -117.14% -320.05% -74.45%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.621M 1.579M 652.0K
YoY Change 1.57% 369.94% -99.9%
NET CHANGE
Cash From Operating Activities -64.80M -71.48M -77.71M
Cash From Investing Activities 31.86M 77.73M 12.55M
Cash From Financing Activities 1.621M 1.579M 652.0K
Net Change In Cash -31.32M 7.831M -64.51M
YoY Change -86.66% -110.37% -110.31%
FREE CASH FLOW
Cash From Operating Activities -$64.80M -$71.48M -$77.71M
Capital Expenditures -$4.350M -$4.391M $7.533M
Free Cash Flow -$60.45M -$67.09M -$85.24M
YoY Change 42.49% 120.66% 51.26%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
9612000
CY2021Q4 sana Success Payment Liabilities Current
SuccessPaymentLiabilitiesCurrent
5000000
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
97108000
CY2022Q2 us-gaap Assets Current
AssetsCurrent
494414000
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
102960000
CY2022Q2 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
97999000
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
3079000
CY2022Q2 sana Success Payment Liabilities Noncurrent
SuccessPaymentLiabilitiesNoncurrent
33517000
CY2022Q2 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
94764000
CY2022Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4825000
CY2022Q2 us-gaap Assets
Assets
971089000
CY2022Q2 us-gaap Goodwill
Goodwill
140627000
CY2022Q2 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
13985000
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
10667000
CY2022Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
59195000
CY2022Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
17991000
CY2022Q2 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
51386000
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
67846000
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
98910000
CY2022Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
10508000
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
72540000
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
19000
CY2022Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1535106000
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
971089000
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-889273000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
639505000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
652000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7755000
CY2022Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-3806000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
701655000
CY2022Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
637000
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-73640000
us-gaap Share Based Compensation
ShareBasedCompensation
17666000
us-gaap Share Based Compensation
ShareBasedCompensation
9099000
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
18556000
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y8M12D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y9M18D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y10M24D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0156
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0046
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0336
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0114
CY2022Q2 us-gaap Liabilities
Liabilities
331584000
CY2022Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
750000000
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
188430000
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
188430000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
2022000
CY2022Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-6347000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
657000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1719000
sana Increase Decrease In Operating Lease Right Of Use Assets And Liabilities
IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilities
-111000
sana Increase Decrease In Operating Lease Right Of Use Assets And Liabilities
IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilities
-3386000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
663000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-373000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
939000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
4378000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
18292000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-90469000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-72904000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
11924000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
90275000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
13767000
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
626405000
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-198000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-72465000
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
187626000
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1175000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
728502000
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
571000
CY2022Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1008000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
9911000
CY2022Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-1175000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-72465000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
639505000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-421184000
CY2021Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
852897000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
298000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4158000
CY2021Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
26000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-180617000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
881983000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
333000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4941000
CY2021Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-43000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
18683000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
905897000
us-gaap Profit Loss
ProfitLoss
-103913000
us-gaap Profit Loss
ProfitLoss
-161934000
us-gaap Depreciation
Depreciation
7414000
us-gaap Depreciation
Depreciation
4853000
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-4358000
sana Change In Fair Value Of Success Payment Liabilities
ChangeInFairValueOfSuccessPaymentLiabilities
-69008000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
3726000
sana Change In Fair Value Of Success Payment Liabilities
ChangeInFairValueOfSuccessPaymentLiabilities
32469000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
5682000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
2838000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
2231000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
631000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2231000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
627036000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-56681000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
550334000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
261848000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
126949000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
205167000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
677283000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
21073000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
3346000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
3414000
sana Cash Received For Amounts Related To Tenant Improvement Allowances
CashReceivedForAmountsRelatedToTenantImprovementAllowances
541000
sana Cash Received For Amounts Related To Tenant Improvement Allowances
CashReceivedForAmountsRelatedToTenantImprovementAllowances
3386000
sana Remeasurement Of Operating Lease Right Of Use Asset For Lease Modifications
RemeasurementOfOperatingLeaseRightOfUseAssetForLeaseModifications
-12801000
us-gaap Nature Of Operations
NatureOfOperations
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1. Organization </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sana Biotechnology, Inc. (the Company or Sana) is a biotechnology company focusing on utilizing engineered cells as medicines. The Company’s operations to date have included identifying and developing potential product candidates, executing preclinical studies, establishing manufacturing capabilities, acquiring technology, organizing and staffing the Company, developing and executing the Company’s business plan, establishing the Company’s intellectual property portfolio, raising capital, and providing general and administrative support for these operations.  </p> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Liquidity and capital resources</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is subject to a number of risks and uncertainties similar to other biotechnology companies in the development stage, including, but not limited to, those related to the need to obtain adequate additional funding, possible failure of preclinical testing or clinical trials, the need to obtain marketing approval for its product candidates, building out internal and external manufacturing capabilities, competitors developing new technological innovations, the need to successfully commercialize and gain market acceptance of the Company’s products, the need to protect the Company’s intellectual property and proprietary technologies, and the need to attract and retain key scientific and management personnel. If the Company does not successfully commercialize or partner any of its product candidates, it will be unable to generate product revenue or achieve profitability. Until such time as the Company can generate significant revenue from product sales, if ever, it expects to finance its operations with the proceeds from additional equity or debt financings or capital obtained in connection with strategic collaborations or licensing or other arrangements. In the event that additional financing is required, the Company may not be able to raise it on terms acceptable to it or at all.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2021, the Company successfully completed the initial public offering (IPO) of its common stock. In connection with the IPO, the Company issued 27.0 million shares of its common stock, including 3.5 million shares pursuant to the full exercise of the underwriters’ option to purchase additional shares, at a price of $25.00 per share, and received $626.4 million in net proceeds, after deducting underwriting discounts and commissions of $45.2 million and offering expenses of $4.0 million. At the closing of the IPO, 134.1 million shares of convertible preferred stock then outstanding were automatically converted into shares of common stock. The related carrying value of the converted preferred stock of $852.9 million was reclassified to common stock and additional paid in-capital.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has incurred operating losses each year since inception and expects such losses to continue for the foreseeable future. As of June 30, 2022, the Company had cash, cash equivalents, and marketable securities of $579.6 million, and an accumulated deficit of $889.3 million, which includes cumulative non-cash charges related to the revaluation of the success payment liabilities and contingent consideration of $31.1 million and $98.1 million, respectively.</p>
CY2022Q2 us-gaap Investments And Cash
InvestmentsAndCash
579600000
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-889300000
sana Change In Fair Value Of Success Payment Liabilities
ChangeInFairValueOfSuccessPaymentLiabilities
31100000
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
98100000
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of estimates </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The Company evaluates its estimates and </p> <p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could materially differ from those estimates. The most significant estimates in the Company’s </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">condensed </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">consolidated financial statements relate to success payment liabilities, contingent consideration, business combinations, accrued expenses, </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">operating lease right-of-use assets and liabilities, </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the valuation </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">stock options. </span></p>
CY2019Q1 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
4.00
us-gaap Restricted Cash And Cash Equivalents Noncurrent Nature Of Restriction Description
RestrictedCashAndCashEquivalentsNoncurrentNatureOfRestrictionDescription
standby letters of credit
CY2022Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
10500000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
8800000
CY2022Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
421900000
CY2022Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
6343000
CY2022Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
3046000
CY2022Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
8000
CY2022Q2 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
424946000
CY2022Q2 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
6351000
CY2021Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
486545000
CY2021Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
1367000
CY2021Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
486545000
CY2021Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
1367000
CY2022Q2 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
424900000
CY2021Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
486500000
CY2022Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
1
CY2021Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
0
us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
CY2021Q2 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
18774000
CY2022Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
94034000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
84238000
CY2022Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
26188000
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
67846000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
65464000
CY2022Q2 us-gaap Depreciation
Depreciation
3800000
CY2021Q2 us-gaap Depreciation
Depreciation
2600000
us-gaap Depreciation
Depreciation
7400000
us-gaap Depreciation
Depreciation
4900000
CY2022Q2 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
9074000
CY2021Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
13814000
CY2022Q2 us-gaap Accrued Vacation Current
AccruedVacationCurrent
5787000
CY2021Q4 us-gaap Accrued Vacation Current
AccruedVacationCurrent
4429000
CY2022Q2 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
3130000
CY2021Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
2888000
CY2022Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
17991000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
21131000
CY2022Q2 sana Accrued Research And Development Services Current
AccruedResearchAndDevelopmentServicesCurrent
6398000
CY2021Q4 sana Accrued Research And Development Services Current
AccruedResearchAndDevelopmentServicesCurrent
3419000
CY2022Q2 sana Accrued Property And Equipment Current
AccruedPropertyAndEquipmentCurrent
2367000
CY2021Q4 sana Accrued Property And Equipment Current
AccruedPropertyAndEquipmentCurrent
2566000
CY2022Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1586000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1971000
CY2022Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
3634000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2388000
CY2022Q2 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
13985000
CY2021Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
10344000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
21183000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
160881000
CY2021Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000.0
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
188400000
CY2022Q2 sana Lessee Operating Lease Liability Payments Due Year Five And Thereafter
LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter
55102000
CY2022Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
44380000
CY2022Q2 sana Lessee Operating Lease Liability Tenant Improvement Allowance
LesseeOperatingLeaseLiabilityTenantImprovementAllowance
2874000
CY2022Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
113627000
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
10667000
CY2022Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
6066000
CY2021Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
4167000
us-gaap Operating Lease Cost
OperatingLeaseCost
11546000
us-gaap Operating Lease Cost
OperatingLeaseCost
7065000
us-gaap Short Term Lease Cost
ShortTermLeaseCost
512000
CY2022Q2 us-gaap Variable Lease Cost
VariableLeaseCost
1903000
CY2021Q2 us-gaap Variable Lease Cost
VariableLeaseCost
1642000
us-gaap Variable Lease Cost
VariableLeaseCost
3392000
us-gaap Variable Lease Cost
VariableLeaseCost
2729000
CY2022Q2 us-gaap Lease Cost
LeaseCost
7969000
CY2021Q2 us-gaap Lease Cost
LeaseCost
5809000
us-gaap Lease Cost
LeaseCost
14938000
us-gaap Lease Cost
LeaseCost
10306000
CY2022Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P6Y8M12D
CY2022Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0963
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
10855000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
25113000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
24326000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
24302000
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
102960000
CY2021Q1 sana Preferred And Common Shares Authorized
PreferredAndCommonSharesAuthorized
800000000.0
CY2021Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
750000000.0
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9911000
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4941000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
17666000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9099000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
17337000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.96
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
141718000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
9853000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
5.98
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
604000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.02
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
970000
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
33123000
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
5889000
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
6.02
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
17934000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-103913000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
11.11
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
25616000
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.90
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
14418000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.70
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.70
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.83
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
15.30
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
3917000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
9464000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-72465000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
18683000
us-gaap Net Income Loss
NetIncomeLoss
-103913000
us-gaap Net Income Loss
NetIncomeLoss
-161934000
CY2021Q2 us-gaap Undistributed Earnings Loss Allocated To Participating Securities Basic
UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
749000
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-72465000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-161934000
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
187626000
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
179899000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
186801000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
149683000
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.39
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.10
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.56
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.08
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-72465000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
18683000
us-gaap Net Income Loss
NetIncomeLoss
-103913000
us-gaap Net Income Loss
NetIncomeLoss
-161934000
CY2021Q2 us-gaap Undistributed Earnings Loss Allocated To Participating Securities Diluted
UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted
749000
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-72465000
CY2021Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
17934000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-103913000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-161934000
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
187626000
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
179899000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
186801000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
149683000
CY2021Q2 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
10609000
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
187626000
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
190508000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
186801000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
149683000
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.39
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.09
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.56
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.08
CY2022Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
28233000
CY2021Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1553000

Files In Submission

Name View Source Status
0001564590-22-028036-index-headers.html Edgar Link pending
0001564590-22-028036-index.html Edgar Link pending
0001564590-22-028036.txt Edgar Link pending
0001564590-22-028036-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
ga1rvcgqctsv000001.jpg Edgar Link pending
grdb4xwsxiff000001.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
sana-10q_20220630.htm Edgar Link pending
sana-10q_20220630_htm.xml Edgar Link completed
sana-20220630.xsd Edgar Link pending
sana-20220630_cal.xml Edgar Link unprocessable
sana-20220630_def.xml Edgar Link unprocessable
sana-20220630_lab.xml Edgar Link unprocessable
sana-20220630_pre.xml Edgar Link unprocessable
sana-ex101_314.htm Edgar Link pending
sana-ex102_295.htm Edgar Link pending
sana-ex311_7.htm Edgar Link pending
sana-ex312_6.htm Edgar Link pending
sana-ex321_8.htm Edgar Link pending
sana-ex322_9.htm Edgar Link pending
Show.js Edgar Link pending